Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.72 SEK 0.1% Market Closed
Market Cap: 684.5m SEK

EV/EBITDA
Enterprise Value to EBITDA

26.4
Current
-5
Median
12.4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
26.4
=
Enterprise Value
1B SEK
/
EBITDA
38.9m SEK
Market Cap EV/EBITDA
SE
Orexo AB
STO:ORX
680.4m SEK 26.4
US
Eli Lilly and Co
NYSE:LLY
722.9B USD 35
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
360.3B USD 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 14
CH
Roche Holding AG
SIX:ROG
206.2B CHF 9.4
CH
Novartis AG
SIX:NOVN
185.9B CHF 10.4
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP 130.6
US
Merck & Co Inc
NYSE:MRK
198.9B USD 8.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
136.3B USD 7.4
EBITDA Growth EV/EBITDA to Growth
SE
Orexo AB
STO:ORX
Average EV/EBITDA: 396.5
26.4
-15%
N/A
US
Eli Lilly and Co
NYSE:LLY
35
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.1
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
90.7
2-Years Forward
EV/EBITDA
191.2
3-Years Forward
EV/EBITDA
38.6